Aleksandra Walewska

Aleksandra Walewska

Auto-generated profile, based on publicly available information

Aleksandra Walewska

Department of Medicinal Chemistry, College of Pharmacy, Skaggs Research Institute, University of Utah Salt Lake City, UT, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2009 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
AWAleksandra Walewska
Aleksandra Walewska
MZMin‐Min Zhang
Min‐Min Zhang
JSJack J. Skalicky
Jack J. Skalicky
DYDoju Yoshikami
Doju Yoshikami
BOBaldomero M. Olivera
Baldomero M. Olivera
GBGrzegorz Bulaj
Grzegorz Bulaj

11 March 2009 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
THTiffany S. Han
Tiffany S. Han
MZMin‐Min Zhang
Min‐Min Zhang
AWAleksandra Walewska
Aleksandra Walewska
PGPawel Gruszczynski
Pawel Gruszczynski
CRCharles R. Robertson
Charles R. Robertson
GBGrzegorz Bulaj
Grzegorz Bulaj

12 January 2008 in Biochemistry
Verified
Journal Article
Closed access
ELEstuardo Lopez-Vera
Estuardo Lopez-Vera
AWAleksandra Walewska
Aleksandra Walewska
JSJack J. Skalicky
Jack J. Skalicky
BOBaldomero M. Olivera
Baldomero M. Olivera
GBGrzegorz Bulaj
Grzegorz Bulaj

3 October 2008 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
AWAleksandra Walewska
Aleksandra Walewska
JSJack J. Skalicky
Jack J. Skalicky
DDDarrell R. Davis
Darrell R. Davis
MZMin-Min Zhang
Min-Min Zhang
ELEstuardo Lopez-Vera
Estuardo Lopez-Vera
GBGrzegorz Bulaj
Grzegorz Bulaj

4 February 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JGJoanna Gajewiak
Joanna Gajewiak
LALayla Azam
Layla Azam
JIJulita Imperial
Julita Imperial
AWAleksandra Walewska
Aleksandra Walewska
BGBrad R. Green
Brad R. Green
MZMin-Min Zhang
Min-Min Zhang
Significance: A biochemically unique cone snail venom peptide has been characterized that may be used to probe unexplored but important features of the diverse voltage-gated Na channel isoforms that underlie electrical signaling in the nervous system. This peptide has a unique posttranslational modification (S-cysteinylated cysteine) and blocks sodium channels by forming a disulfide bond with the channel at a distinctive binding site. Because block by the peptide is prevented when specific β-subunits are coexpressed, this neurotoxin has potential for assessing which β-subunits are present in native Na channels. Peptide activity depends on the oxidation state of extracellular Cys residues on the channel. Thus, this peptide can also be used to monitor the oxidation state of the targeted Na channels.

10 February 2015 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HLHee-Kyoung Lee
Hee-Kyoung Lee
LZLiuyin Zhang
Liuyin Zhang
MSMisty D. Smith
Misty D. Smith
AWAleksandra Walewska
Aleksandra Walewska
NVNadeem A. Vellore
Nadeem A. Vellore
GBGrzegorz Bulaj
Grzegorz Bulaj
Neurotensin receptors have been studied as molecular targets for the treatment of pain, schizophrenia, addiction, or cancer. Neurotensin (NT) and Contulakin-G, a glycopeptide isolated from a predatory cone snail Conus geographus, share a sequence similarity at the C-terminus, which is critical for activation of neurotensin receptors. Both peptides are potent analgesics, although affinity and agonist potency of Contulakin-G toward neurotensin receptors are significantly lower, as compared to those for NT. In this work, we show that the weaker agonist properties of Contulakin-G result in inducing significantly less desensitization of neurotensin receptors and preserving their cell-surface density. Structure-activity relationship (SAR) studies suggested that both glycosylation and charged amino acid residues in Contulakin-G or NT played important roles in desensitizing neurotensin receptors. Computational modeling studies of human neurotensin receptor NTS1 and Contulakin-G confirmed the role of glycosylation in weakening interactions with the receptors. Based on available SAR data, we designed, synthesized and characterized an analog of Contulakin-G in which the glycosylated amino acid residue, Gal-GalNAc-Thr10, was replaced by memantine-Glu10 residue. This analog exhibited comparable agonist potency and weaker desensitization properties as compared to that of Contulakin-G, while producing analgesia in the animal model of acute pain following systemic administration. We discuss our study in the context of feasibility and safety of developing NT therapeutic agents with improved penetration across the blood-brain barrier. Our work supports engineering peptide-based agonists with diverse abilities to desensitize G-protein coupled receptors and further emphasizes opportunities for conotoxin as novel pharmacological tools and drug candidates.